title: Outside the Black Box: Re-assessing Pediatric Antidepressant Prescription.
abstract: OBJECTIVE
  The purpose of this review is to assess whether evidence supports a favorable risk/benefit profile for pediatric antidepressant use and reconsideration of the black box.
  
  
  METHODS
  The review examines studies post-black box purporting to show declines in pediatric antidepressant use and rising youth suicide, summarizes evidence for efficacy and safety of pediatric antidepressants, and discusses irregularities in recent meta-analyses of fluoxetine for youth.
  
  
  RESULTS
  Pediatric antidepressant prescription did not significantly decline post-black box and youth suicide has risen only in recent years. Recent meta-analyses fail to undermine evidence that antidepressants are associated with increased risk of suicidality in youth.
  
  
  CONCLUSIONS
  First line prescription of antidepressants for youth is not advisable. The black box and international warnings on pediatric use of antidepressants are warranted. Wider availability of psychosocial options for depressed youth is recommended.
authors: University of Rhode Island, Kingston, Rhode Island, USA.
authors: Jacqueline A
authors: JA
authors: Sparks
authors: Barry L
authors: BL
authors: Duncan
keywords: SSRIs; adolescents; antidepressants; black box; children; suicide
references: Am J Psychiatry. 2007 Sep;164(9):1356-63
references: 17728420
references: J Am Acad Child Adolesc Psychiatry. 2005 Sep;44(9):915-24
references: 16113620
references: Psychiatr Serv. 2011 Jul;62(7):727-33
references: 21724784
references: JAMA. 2004 Aug 18;292(7):807-20
references: 15315995
references: Pediatrics. 2012 Jul;130(1):23-31
references: 22711728
references: JAMA Psychiatry. 2013 Jan;70(1):121-2
references: 23303283
references: Am J Psychiatry. 2007 Jul;164(7):1035-43
references: 17606655
references: PLoS One. 2012;7(3):e33181
references: 22427983
references: Pediatrics. 2007 Nov;120(5):e1313-26
references: 17974724
references: Arch Gen Psychiatry. 2012 Jun;69(6):572-9
references: 22393205
references: Arch Gen Psychiatry. 2012 Jun;69(6):580-7
references: 22309973
references: NCHS Data Brief. 2010 Sep;(42):1-8
references: 20854747
references: J Am Acad Child Adolesc Psychiatry. 2009 Oct;48(10):997-1004
references: 20854770
references: Arch Gen Psychiatry. 1997 Nov;54(11):1031-7
references: 9366660
references: Arch Gen Psychiatry. 2008 Jan;65(1):94-101
references: 18180433
references: Br J Psychiatry. 2008 Jul;193(1):10-7
references: 18700212
references: BMJ. 2004 Apr 10;328(7444):879-83
references: 15073072
references: J Am Acad Child Adolesc Psychiatry. 2009 Oct;48(10):987-996
references: 19730274
references: J Child Adolesc Psychopharmacol. 2006 Feb-Apr;16(1-2):25-32
references: 16553526
references: Arch Gen Psychiatry. 2006 Aug;63(8):865-72
references: 16894062
references: JAMA. 2008 Feb 27;299(8):901-913
references: 18314433
references: JAMA. 2007 Apr 18;297(15):1683-96
references: 17440145
references: Arch Gen Psychiatry. 2007 Oct;64(10):1132-43
references: 17909125
references: Psychother Psychosom. 2013;82(3):132-41
references: 23548764
references: Am J Psychiatry. 2010 Jul;167(7):782-91
references: 20478877
references: Arch Gen Psychiatry. 2006 Mar;63(3):332-9
references: 16520440
references: Psychiatr Serv. 2004 Apr;55(4):387-91
references: 15067149
references: Lancet. 2004 Apr 24;363(9418):1341-5
references: 15110490
references: Arch Gen Psychiatry. 2007 Apr;64(4):466-72
references: 17404123
references: Expert Opin Pharmacother. 2012 Oct;13(15):2119-30
references: 22984934
references: Pediatrics. 2002 May;109(5):721-7
references: 11986427
references: J Am Acad Child Adolesc Psychiatry. 2002 Oct;41(10):1205-15
references: 12364842
references: Pharmacoepidemiol Drug Saf. 2010 Feb;19(2):158-74
references: 20049836
references: Am J Psychiatry. 2007 Jun;164(6):884-91
references: 17541047
references: J Clin Psychiatry. 2009 Apr 21;70(5):741-7
references: 19552869
references: Drug Saf. 2009;32(4):275-82
references: 19388719